Skip to content
Screener

MiMedx Group MDXG Wound — Net Sales

Other product segments

Surgical
$39.3M+15.1%

Similar metrics at other companies

General Mills logo
GISPet — Net Sales
$746.6M+5.8%
Wabash National logo
WNCNew trailers — Net Sales
$317.05M+1.6%
Amazon logo
AMZNNet product sales — Net Sales
$71.3B+11.5%
Amazon logo
AMZNNet service sales — Net Sales
$110.22B+20.2%
Lowe's Companies logo
LOWOther Sales — Net Sales
$551M+30.0%
Lowe's Companies logo
LOWPaint Sales — Net Sales
$1.25B+0.4%

Other financials

Income statement

See full
Revenue$64.4M-34.7%
Gross profit$44.4M-44.5%
Operating income-$18.5M-249%
Net income-$14.8M-254%
EPS (diluted)-$0.10-267%

Balance sheet

See full
Cash & equivalents$135.8M+14.3%
Total debt$17.2M-6.8%
Total equity$216.0M-0.3%
Total assets$281.0M-3.5%

Cash flow

See full
Operating cash flow-$10.0M-169%
CapEx$598.0K+234%
Free cash flow-$10.6M-175%

Valuation

See full
Market cap$632.6M-39.3%
Enterprise value$513.97M-45.4%
P/E101.4×+69.0×
P/S1.8×-1.1×

Profitability

See full
Gross margin78.8%-2.6pp
Operating margin2.5%-9.3pp
Net margin1.8%-7.1pp
FCF margin12.5%-3.2pp

Returns & leverage

See full
Return on equity2.9%-13.8pp
Debt / equity0.1×0.0×
Current ratio5.3×+0.9×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: MiMedx Group’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001376339-26-000071
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Surgical$39,29734,12975,67166,261
Wound25,06564,47647,682120,549
Net sales$64,362$98,605$123,353$186,810

Item 1. Financial Statements

FAQ

What is MiMedx Group's wound — net sales?
MiMedx Group (MDXG) reported wound — net sales of $25.07M in Q2 2026.
How has MiMedx Group's wound — net sales changed year-over-year?
MiMedx Group's wound — net sales decreased by 61.1% year-over-year, from $64.48M to $25.07M.
What is the long-term trend for MiMedx Group's wound — net sales?
Over 3 years (2022 to 2025), MiMedx Group's wound — net sales has grown at a 16.2% compound annual growth rate (CAGR), from $175.97M to $276.33M.
What does wound — net sales mean?
This metric represents the total revenue generated from the sale of regenerative biomaterial products and bioimplants specifically designed for wound care applications. It reflects the market demand and commercial adoption of the company's amniotic tissue-based therapies within clinical settings. Tracking this figure helps investors assess the growth trajectory and competitive positioning of the company's primary therapeutic segment.

Ask your AI about MiMedx Group's wound — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude